This site is intended for health professionals only
Saturday 15 December 2018
Share |

Topic: Diabetes

September 28, 2018

Hannah Beba is a senior pharmacist practising in the diabetes and endocrinology fields at the County Durham and Darlington NHS Foundation Trust. She is also one of the charity Diabetes UK clinical champions and an independent prescriber.
 
She talks to Léa Legraien about her successes, challenges and love for the profession.
 
 
Q Why did you become a pharmacist?
 
 

March 7, 2018
Danish pharmaceutical company Novo Nordisk’s diabetes drug, semaglutide, which could also be used to treat obesity, has passed its first Phase III clinical trial. Semaglutide is taken once daily as a tablet and works by increasing insulin production

As rates of diabetes continue to rise, the hunt for new drugs to tackle the metabolic disease is imperative. In 2014 there were an estimated 422 million people with diabetes, compared to just 108 million in 1980.

Although there are a range of treatment options available for type 2 diabetes, many target the symptoms rather than the root cause and may have adverse side effects. A further difficulty is the close connection between diabetes and obesity, which is causing cases to increase.

May 19, 2017
The Forum for Injection Technique (FIT) UK has published the latest edition of its UK Injection and Infusion Technique Recommendations

The Forum for Injection Technique (FIT) UK, which provides evidence-based best practice recommendations on diabetes injection technique, has published the latest edition of its UK Injection and Infusion Technique Recommendations, including for the first time a new set of six ‘Golden Rules’.

September 15, 2015
Patients treated with Xultophy® achieved significant improvements in treatment related impact measurements compared to intensifying insulin glargine

Data from the DUAL™ V trial investigating the efficacy and safety of Xultophy® (insulin degludec/liraglutide; IDegLira), in type 2 diabetes patients (T2D) uncontrolled on insulin glargine, were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting. (1)

March 11, 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

February 23, 2015
EKF Diagnostics, the global diagnostics company, announced that it has introduced a new diabetic biomarker test that provides a 2–3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2–3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycaemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and haemodialysis. (1)

EKF Diagnostics, the global diagnostics company, announced that it has introduced a new diabetic biomarker test that provides a 2–3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2–3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycaemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and haemodialysis. (1)

 

August 9, 2012
The EKF Diagnostics Group’s recent attendance at the AACC Clinical Lab Expo 2012 at the Los Angeles Convention Center, California highlighted the positive clinical support of their range of IVD solutions to monitor and diagnose diabetes and ketosis.
Renowned point-of-care expert, Dr James Nichols, Professor of Pathology at Tufts University School of Medicine, Boston, and Medical Director of Clinical Chemistry for Baystate Health in Springfield, Massachusetts, demonstrated the clinical efficacy of Beta-Hydroxybutyrate (β-HB) to measure the main ketone produced during ketosis.
October 21, 2009
Sanofi-Aventis is paying Wellstat Therapeutics up to $350 million to license the potential Type II diabetes drug PN2034

Sanofi-Aventis is paying Wellstat Therapeutics up to $350 million to license the potential Type II diabetes drug PN2034.

The drug is in mid-stage development, and the deal will give Sanofi an exclusive worldwide license to develop, manufacture and market both it and related compounds.

Wellstat will receive cash upfront plus additional payments when certain commercial milestones are met, plus royalties on worldwide sales.

September 28, 2009
Boehringer Ingelheim’s diabetes pipeline continues to advance as the company announces conclusion of robust phase III pivotal trials programme for linagliptin

Following the release of linagliptin phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal phase III clinical trials. The company confirmed that first results from the phase III clinical trials programme consistently support the favourable efficacy and safety profile already observed in earlier linagliptin investigational studies, such as the phase II data which had shown significant results in haemoglobin A1c (HbA1c)-lowering (-0,73 percent, 5 mg dose) and a safety profile comparable to placebo.

September 16, 2009
US scientists have discovered that breast cancer tumours can be shrunk more quickly when a common diabetes treatment is added to chemotherapy

US scientists have discovered that breast cancer tumours can be shrunk more quickly when a common diabetes treatment is added to chemotherapy.

Researchers discovered that the drug metformin appeared to target breast cancer stem cells – which are resistant to conventional therapy – in mice, raising hopes of a more effective means of treating the disease in humans.

July 7, 2009
A once-a-day injection which stimulates the release of insulin has been launched to treat type 2 diabetes and obese people

A once-a-day injection which stimulates the release of insulin has been launched to treat type 2 diabetes and obese people.

The drug Victoza, also called liraglutide, releases insulin when blood sugar levels become too high and trials found that it helped people lose weight by increasing the "full" feeling. It also lowered blood pressure.

Of the two million people with type 2 diabetes in the UK many are overweight or obese and a further 500,000 people have type 2 but do not know it.

June 5, 2009
A researcher at health care giant Johnson & Johnson has said the company will develop better-targeted drugs capable of curing cancer

A researcher at health care giant Johnson & Johnson (J&J) has said the company will develop better-targeted drugs capable of curing cancer.

Dr William Hait, who joined the company in 2007, told analysts that the company is aiming to become a leader in cancer therapy within the next five years.

As well as creating drugs to cure, prevent or stifle cancer, J&J researchers are also concentrating their efforts on areas of unmet medical need, including diabetes, hepatitis C and HIV.

June 4, 2009
Cancer treatment could be "revolutionised" thanks to a drug commonly prescribed for diabetes, researchers have claimed

Cancer treatment could be "revolutionised" thanks to a drug commonly prescribed for diabetes, researchers have claimed.

Scientists in the US and Canada have discovered that an important immune system defence against cancer is boosted by the drug metformin.

Promising new cancer therapies could be provided if the medicine is used in conjunction with vaccines, they believe. The effectiveness of antiviral vaccines could also be enhanced by the use of metformin.

June 4, 2009
New results from a one-year phase III study have confirmed that the investigational biological therapy Ilaris® produced rapid and sustained remission of symptoms in patients with CAPS

New results from a one-year phase III study have confirmed that the investigational biological therapy Ilaris® (canakinumab, formerly ACZ885) produced rapid and sustained remission of symptoms in the majority of children and adults with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS).
 

June 1, 2009
New data has revealed that Next Generation FlexPen®, Novo Nordisk’s prefilled insulin delivery device, has a significantly lower injection force than SoloStar® and KwikPen®

New data published this week in Expert Opinion Pharmacotherapy has revealed that Next Generation FlexPen®, Novo Nordisk's prefilled insulin delivery device, has a significantly lower injection force than two other devices, SoloStar® and KwikPen®. Previous studies show that people with diabetes prefer a lower injection force.

March 9, 2009
Diabetic care is suffering due to lack of training and failure to provide consistent care for patients

Diabetics are being failed by doctors and nurses who are too ready to prescribe drugs rather than follow treatment guidelines, it is alleged.

Dr Rob Andrews will tell the Diabetes UK's Annual Professional Conference in Glasgow that lack of training, too few dieticians and government targets are largely to blame.

International and UK guidelines say that weight-management and exercise advice should be given before medication is prescribed to people with type 2 diabetes.

October 8, 2008
Report says NHS is spending £9 billion a year on treating diabetes

The NHS spends about £1 million an hour treating diabetes and its complications, a new report claims.

Hospitals and primary care trusts spend up to 10% of the NHS budget – or £9 billion – each year dealing with repercussions from the disease such as blindness, kidney failure, stroke, heart disease and limb amputation.

The figures were drawn up by the charity Diabetes UK using data from the Department of Health and NHS spend in 2007/08.

May 22, 2008
ADVANCE trials will have “huge implications” for type 2 diabetes patients worldwide

ADVANCE (Action in Diabetes and Vascular Disease), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, is now complete.

The second and final part of this five-year trial investigates the effect of intensive blood glucose lowering treatment on major macrovascular (cardiovascular death, MI, stroke) and microvascular (kidney and eye disease) events.

May 14, 2008
A US study reports on chronic disease management programmes serving low-income individuals

A US study published in the May/June issue of Health Affairs reports on the first randomised trial providing a scientifically valid look at what one might expect from chronic disease management programmes that serve low-income individuals.

May 12, 2008
A pilot scheme designed to reduce acute care in certain patients has been rolled out

A pilot scheme designed to help reduce the use of acute hospital care by patients with complex health and social care needs has been rolled out in the UK's Kent, Cornwall and Newham.

The £31 million Whole System Demonstrator Programme aims to give people the support necessary to help them retain their independence in the community and improve their quality of life by managing their conditions in their own homes.

March 14, 2008
The UK's Royal Bournemouth Hospital trials a system allowing diabetes patients to submit test results via the Internet

A hospital is piloting an innovative system which allows diabetic patients to monitor their blood sugar levels remotely.

Patients at the Royal Bournemouth Hospital in Dorset, in the UK, can now carry out the tests at home, and send their results back to be analysed over the internet.

Healthcare professionals then examine the data, and give 24-hour advice on how to manage the condition.

December 13, 2007
Smoking is linked to a significantly increased risk of developing type 2 diabetes, US researchers suggest

Smoking is linked to a significantly increased risk of developing type 2 diabetes, US research suggests.

The University of Lausanne looked at 25 studies involving 1.2 million patients.

They found smokers had a 44% increased risk of type 2 diabetes compared with non-smokers - with the risk rising with the number of cigarettes smoked.

The Journal Of The American Medical Association study found the increased risk for those who smoked at least 20 cigarettes a day rose to 61%.

For lighter smokers the risk was 29% higher than for a non-smoker.